Rubix Group (HK) Limited is a private single family office that holds and monitors, on a passive and own-account basis, the family's interests in healthcare and life sciences. This website is informational only — Rubix Group is not a public-facing investment manager, does not raise capital, and does not offer services to third parties.
Rubix Group (HK) Limited is a Hong Kong incorporated private single family office established in 2020 to hold and monitor the assets and investments of its controlling family and family-owned investment holding vehicles. Rubix Group serves only members of that family group; it does not offer services to the public and does not solicit, accept, or manage capital, mandates, or investment instructions from persons outside the family group.
The family's own capital is allocated, on a passive and own-account basis, to a small number of healthcare and life sciences interests identified through the family's personal and professional relationships worldwide. Rubix Group does not manage money for others, does not offer or market any investment product or service, and does not carry on any business of a regulated activity.
Regulatory status. Rubix Group (HK) Limited is not licensed by the Securities and Futures Commission of Hong Kong and does not carry on any business of a regulated activity under the Securities and Futures Ordinance (Cap. 571), including Type 1 (dealing in securities), Type 4 (advising on securities), or Type 9 (asset management). Any reference on this website to a "single family office" or to Hong Kong's family office tax concession relates to tax treatment only and does not imply SFC authorisation, licensing, or regulated status.
Rubix Group's approach reflects its nature as a private family office rather than a public-facing manager: capital is committed for the family's own account, without solicitation, promotion, or public offering, and with a long-term, unhurried orientation.
All capital held or allocated by Rubix Group belongs to its controlling family. Rubix Group does not raise, pool, or manage capital on behalf of any other person, and does not offer fund, co-investment, or advisory arrangements to third parties.
Interests are held with a multi-year perspective, without pressure to generate liquidity events or a public track record. Rubix Group is comfortable with concentration and illiquidity where family conviction warrants it.
Consistent with its private, family-only mandate, Rubix Group does not publicise its holdings, does not seek public recognition for its investment activity, and maintains confidentiality regarding the family's affairs.
The family's healthcare and life sciences interests span several sub-sectors globally. The categories below describe areas the family follows and has historically held interests in for its own account; they are provided for information only and do not represent an offer, invitation, or solicitation to invest.
The global biotech ecosystem continues to mature, producing novel biologics, small-molecule therapeutics, and innovative drug candidates. The family's interests in this area span the development lifecycle, from earlier-stage science through to commercialisation.
The medical device sector continues to evolve through domestic innovation, regulatory change, and rising healthcare expenditure across markets worldwide. The family's interests here favour companies developing differentiated technologies with durable commercial relevance.
Ageing populations and expanding insurance coverage continue to reshape healthcare services globally. The family holds selective interests in providers and infrastructure positioned to benefit from structural, long-term demand growth.
The family follows the convergence of technology and healthcare globally — from AI-driven drug discovery and computational biology through telemedicine platforms, real-world evidence analytics, and the digital infrastructure enabling precision medicine at scale.
Rubix Group is led by a single executive responsible for the family's own-account healthcare and life sciences interests, informed by decades of cross-jurisdictional experience.
Alexander Ariana serves as Chief Executive Officer of Rubix Group (HK) Limited, with responsibility for the family's own-account healthcare and life sciences interests. He oversees the family's ongoing review of its holdings and maintains the family's relationships across biotech and therapeutics, medical devices, healthcare services, and digital health.
His background spans cross-jurisdictional capital allocation and family office administration. He brings a disciplined, long-term perspective to the family's holdings and maintains a private, informational approach consistent with Rubix Group's family-only mandate.
"We believe patient, own-account capital — held without the pressures of solicitation or public promotion — is best positioned to support genuine long-term conviction in healthcare and life sciences."
Rubix Group (HK) Limited is a private single family office. It does not accept external capital, investment mandates, or unsolicited proposals, and this website does not constitute a means of soliciting or transacting business with the public.